{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:02:53Z","timestamp":1793656973793,"version":"4.5.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting the contact activation system through Factor XI (FXI) or Factor XII (FXII) inhibition represents a major paradigm shift in antithrombotic therapy for ischemic stroke. Unlike traditional anticoagulants, contact pathway factors drive pathological thrombus propagation and thromboinflammation; crucially, while FXII plays a negligible role in physiological hemostasis, FXI contributes only secondarily, thereby substantially uncoupling antithrombotic efficacy from major bleeding risk. However, a notable disconnect exists between experimental models and clinical development. Preclinical stroke literature, primarily rodent middle cerebral artery occlusion (MCAO) models, is overwhelmingly concentrated on FXII targeting, where FXII deficiency or blockade consistently reduces cerebral infarct volumes, preserves microvascular perfusion, and attenuates thromboinflammation, whereas experimental studies of direct FXI treatment remain sparse. Conversely, human clinical translation has focused largely on oral FXIa inhibitors, maintaining a favorable bleeding profile across indications but yielding mixed efficacy, ranging from neutral Phase II studies and the early termination of OCEANIC-AF to positive secondary stroke prevention data. Following positive OCEANIC-STROKE findings, asundexian (under FDA priority review as of September 2026) emerges as a prospective add-on to antiplatelet therapy for the secondary prevention of noncardioembolic stroke or high-risk TIA, particularly in nonlacunar or atherosclerotic populations. Reconciling preclinical FXII data with clinical FXIa trial outcomes provides a timely rationale to systematically review evidence across MCAO models and human stroke trials to delineate the distinct therapeutic potentials of FXI and FXII inhibition.<\/jats:p>","DOI":"10.1186\/s42466-026-00540-1","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:02:36Z","timestamp":1792166556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FXI and FXII in experimental stroke and FXI in clinical stroke trials"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-9399","authenticated-orcid":false,"given":"Stine","family":"Mencl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Langhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"K\u00fchne Escol\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6hrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"2","key":"540_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cll.2026.02.003","volume":"46","author":"JI Weitz","year":"2026","unstructured":"Weitz, J. I., & Gailani, D. (2026). Pharmacologic Factor XI\/XIa Inhibitors: What the Laboratory Hematologist Needs to Know. Clinics In Laboratory Medicine, 46(2), 243\u2013258.","journal-title":"Clinics In Laboratory Medicine"},{"issue":"12","key":"540_CR2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","volume":"31","author":"DV Kalinin","year":"2021","unstructured":"Kalinin, D. V. (2021). Factor XII(a) inhibitors: a review of the patent literature. Expert Opinion On Therapeutic Patents, 31(12), 1155\u20131176.","journal-title":"Expert Opinion On Therapeutic Patents"},{"issue":"3","key":"540_CR3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-012-0186-5","volume":"3","author":"PY Leung","year":"2012","unstructured":"Leung, P. Y., Hurst, S., Berny-Lang, M. A., Verbout, N. G., Gailani, D., Tucker, E. I., Wang, R. K., McCarty, O. J., & Gruber, A. (2012). Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Translational stroke research, 3(3), 381\u2013389.","journal-title":"Translational stroke research"},{"issue":"3","key":"540_CR4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","volume":"203","author":"C Kleinschnitz","year":"2006","unstructured":"Kleinschnitz, C., Stoll, G., Bendszus, M., Schuh, K., Pauer, H. U., Burfeind, P., Renne, C., Gailani, D., Nieswandt, B., & Renne, T. (2006). Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. The Journal of experimental medicine, 203(3), 513\u2013518.","journal-title":"The Journal of experimental medicine"},{"issue":"5","key":"540_CR5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/th14-04-0311","volume":"112","author":"J Bjorkqvist","year":"2014","unstructured":"Bjorkqvist, J., Nickel, K. F., Stavrou, E., & Renne, T. (2014). In vivo activation and functions of the protease factor XII. Thrombosis and haemostasis, 112(5), 868\u2013875.","journal-title":"Thrombosis and haemostasis"},{"issue":"18","key":"540_CR6","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/bloodadvances.2021004567","volume":"5","author":"RA Malik","year":"2021","unstructured":"Malik, R. A., Zhou, J., Fredenburgh, J. C., Truong, T. K., Crosby, J. R., Revenko, A. S., & Weitz, J. I. (2021). Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Adv, 5(18), 3540\u20133551.","journal-title":"Blood Adv"},{"issue":"1","key":"540_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1172\/JCI108754","volume":"60","author":"HL Meier","year":"1977","unstructured":"Meier, H. L., Pierce, J. V., Colman, R. W., & Kaplan, A. P. (1977). Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. The Journal of clinical investigation, 60(1), 18\u201331.","journal-title":"The Journal of clinical investigation"},{"key":"540_CR8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pneurobio.2018.01.003","volume":"165\u2013167","author":"A Nokkari","year":"2018","unstructured":"Nokkari, A., Abou-El-Hassan, H., Mechref, Y., Mondello, S., Kindy, M. S., Jaffa, A. A., & Kobeissy, F. (2018). Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms. Progress in neurobiology, 165\u2013167, 26\u201350.","journal-title":"Progress in neurobiology"},{"issue":"22","key":"540_CR9","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","volume":"120","author":"T Renne","year":"2012","unstructured":"Renne, T., Schmaier, A. H., Nickel, K. F., Blomback, M., & Maas, C. (2012). In vivo roles of factor XII. Blood, 120(22), 4296\u20134303.","journal-title":"Blood"},{"key":"540_CR10","doi-asserted-by":"crossref","unstructured":"Wei, L. K., Griffiths, L. R., Kooi, C. W., Irene, L.: Meta-Analysis of Factor, & Factor, V. (2019). VII, Factor XII, and Factor XIII-A Gene Polymorphisms and Ischemic Stroke. Medicina (Kaunas) 55(4).","DOI":"10.3390\/medicina55040101"},{"issue":"10","key":"540_CR11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.192.10.1415","volume":"192","author":"K Persson","year":"2000","unstructured":"Persson, K., Morgelin, M., Lindbom, L., Alm, P., Bjorck, L., & Herwald, H. (2000). Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. The Journal of experimental medicine, 192(10), 1415\u20131424.","journal-title":"The Journal of experimental medicine"},{"issue":"13","key":"540_CR12","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/CIRCULATIONAHA.109.924761","volume":"121","author":"I Hagedorn","year":"2010","unstructured":"Hagedorn, I., Schmidbauer, S., Pleines, I., Kleinschnitz, C., Kronthaler, U., Stoll, G., Dickneite, G., & Nieswandt, B. (2010). Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation, 121(13), 1510\u20131517.","journal-title":"Circulation"},{"issue":"1","key":"540_CR13","doi-asserted-by":"crossref","first-page":"e0146783","DOI":"10.1371\/journal.pone.0146783","volume":"11","author":"J Krupka","year":"2016","unstructured":"Krupka, J., May, F., Weimer, T., Pragst, I., Kleinschnitz, C., Stoll, G., Panousis, C., Dickneite, G., & Nolte, M. W. (2016). The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia\/Reperfusion Injury in Rats. Plos One, 11(1), e0146783.","journal-title":"Plos One"},{"issue":"5","key":"540_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00018-022-04257-7","volume":"79","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Shen, C., Fang, M., Han, Y., Long, C., Liu, W., Yang, M., Liu, M., Zhang, D., Cao, Q., et al. (2022). Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke. Cellular And Molecular Life Sciences, 79(5), 240.","journal-title":"Cellular And Molecular Life Sciences"},{"key":"540_CR15","doi-asserted-by":"crossref","first-page":"177497","DOI":"10.1016\/j.ejphar.2025.177497","volume":"998","author":"W Wang","year":"2025","unstructured":"Wang, W., Zhang, Y., Fang, Y., Gao, J., Thuku, R. C., Yang, J., Na, C., Lu, Q., & Fang, M. (2025). Targeting the contact-kinin system: A cyclopeptide with anti-thromboinflammatory properties against stroke. European journal of pharmacology, 998, 177497.","journal-title":"European journal of pharmacology"},{"issue":"5","key":"540_CR16","first-page":"1001","volume":"45","author":"LN Cha","year":"2024","unstructured":"Cha, L. N., Yang, J., Gao, J. A., Lu, X., Chang, X. L., Thuku, R. C., Liu, Q., Lu, Q. M., Li, D. S., Lai, R., et al. (2024). Bat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential. Zool Res, 45(5), 1001\u20131012.","journal-title":"Zool Res"},{"issue":"16","key":"540_CR17","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.molimm.2008.06.028","volume":"45","author":"AE Davis","year":"2008","unstructured":"Davis, A. E. 3rd, Mejia, P., & Lu, F. (2008). Biological activities of C1 inhibitor. Molecular immunology, 45(16), 4057\u20134063.","journal-title":"Molecular immunology"},{"issue":"9","key":"540_CR18","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1161\/STROKEAHA.112.660340","volume":"43","author":"N Heydenreich","year":"2012","unstructured":"Heydenreich, N., Nolte, M. W., Gob, E., Langhauser, F., Hofmeister, M., Kraft, P., Albert-Weissenberger, C., Brede, M., Varallyay, C., Gobel, K., et al. (2012). C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke, 43(9), 2457\u20132467.","journal-title":"Stroke"},{"key":"540_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbi.2021.01.002","volume":"93","author":"D Mercurio","year":"2021","unstructured":"Mercurio, D., Piotti, A., Valente, A., Oggioni, M., Ponstein, Y., Van Amersfoort, E., Gobbi, M., Fumagalli, S., & De Simoni, M. G. (2021). Plasma-derived and recombinant C1 esterase inhibitor: Binding profiles and neuroprotective properties in brain ischemia\/reperfusion injury. Brain behavior and immunity, 93, 299\u2013311.","journal-title":"Brain behavior and immunity"},{"issue":"10382","key":"540_CR20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig, T. J., Reshef, A., Li, H. H., Jacobs, J. S., Bernstein, J. A., Farkas, H., Yang, W. H., Stroes, E. S. G., Ohsawa, I., Tachdjian, R., et al. (2023). Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 401(10382), 1079\u20131090.","journal-title":"Lancet"},{"issue":"11","key":"540_CR21","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/jth.15488","volume":"19","author":"S Beck","year":"2021","unstructured":"Beck, S., Stegner, D., Loroch, S., Baig, A. A., Gob, V., Schumbrutzki, C., Eilers, E., Sickmann, A., May, F., Nolte, M. W., et al. (2021). Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents. Journal of thrombosis and haemostasis: JTH, 19(11), 2835\u20132840.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"15","key":"540_CR22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","volume":"143","author":"SA Moellmer","year":"2024","unstructured":"Moellmer, S. A., Puy, C., & McCarty, O. J. T. (2024). Biology of factor XI. Blood, 143(15), 1445\u20131454.","journal-title":"Blood"},{"issue":"1","key":"540_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3181\/00379727-82-20057","volume":"82","author":"RL Rosenthal","year":"1953","unstructured":"Rosenthal, R. L., Dreskin, O. H., & Rosenthal, N. (1953). New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proceedings Of The Society For Experimental Biology And Medicine, 82(1), 171\u2013174.","journal-title":"Proceedings Of The Society For Experimental Biology And Medicine"},{"key":"540_CR24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","volume":"161","author":"BM Mohammed","year":"2018","unstructured":"Mohammed, B. M., Matafonov, A., Ivanov, I., Sun, M. F., Cheng, Q., Dickeson, S. K., Li, C., Sun, D., Verhamme, I. M., Emsley, J., et al. (2018). An update on factor XI structure and function. Thrombosis research, 161, 94\u2013105.","journal-title":"Thrombosis research"},{"issue":"12","key":"540_CR25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","volume":"11","author":"A Matafonov","year":"2013","unstructured":"Matafonov, A., Cheng, Q., Geng, Y., Verhamme, I. M., Umunakwe, O., Tucker, E. I., Sun, M. F., Serebrov, V., Gruber, A., & Gailani, D. (2013). Evidence for factor IX-independent roles for factor XIa in blood coagulation. Journal of thrombosis and haemostasis: JTH, 11(12), 2118\u20132127.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"7","key":"540_CR26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jth.12295","volume":"11","author":"C Puy","year":"2013","unstructured":"Puy, C., Tucker, E. I., Wong, Z. C., Gailani, D., Smith, S. A., Choi, S. H., Morrissey, J. H., Gruber, A., & McCarty, O. J. (2013). Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. Journal of thrombosis and haemostasis: JTH, 11(7), 1341\u20131352.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"19","key":"540_CR27","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood-2012-12-473629","volume":"121","author":"Y Geng","year":"2013","unstructured":"Geng, Y., Verhamme, I. M., Smith, S. B., Sun, M. F., Matafonov, A., Cheng, Q., Smith, S. A., Morrissey, J. H., & Gailani, D. (2013). The dimeric structure of factor XI and zymogen activation. Blood, 121(19), 3962\u20133969.","journal-title":"Blood"},{"issue":"7","key":"540_CR28","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2010.03899.x","volume":"8","author":"MF Whelihan","year":"2010","unstructured":"Whelihan, M. F., Orfeo, T., Gissel, M. T., & Mann, K. G. (2010). Coagulation procofactor activation by factor XIa. Journal of thrombosis and haemostasis: JTH, 8(7), 1532\u20131539.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"4","key":"540_CR29","doi-asserted-by":"crossref","first-page":"e0152968","DOI":"10.1371\/journal.pone.0152968","volume":"11","author":"CE Bane Jr","year":"2016","unstructured":"Bane, C. E. Jr., Ivanov, I., Matafonov, A., Boyd, K. L., Cheng, Q., Sherwood, E. R., Tucker, E. I., Smiley, S. T., McCarty, O. J., Gruber, A., et al. (2016). Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. Plos One, 11(4), e0152968.","journal-title":"Plos One"},{"issue":"19","key":"540_CR30","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1016\/S0021-9258(19)85161-X","volume":"260","author":"CF Scott","year":"1985","unstructured":"Scott, C. F., Silver, L. D., Purdon, A. D., & Colman, R. W. (1985). Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. The Journal of biological chemistry, 260(19), 10856\u201310863.","journal-title":"The Journal of biological chemistry"},{"issue":"3","key":"540_CR31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","volume":"102","author":"A Gruber","year":"2003","unstructured":"Gruber, A., & Hanson, S. R. (2003). Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood, 102(3), 953\u2013955.","journal-title":"Blood"},{"issue":"4","key":"540_CR32","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","volume":"113","author":"EI Tucker","year":"2009","unstructured":"Tucker, E. I., Marzec, U. M., White, T. C., Hurst, S., Rugonyi, S., McCarty, O. J., Gailani, D., Gruber, A., & Hanson, S. R. (2009). Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood, 113(4), 936\u2013944.","journal-title":"Blood"},{"issue":"3","key":"540_CR33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/ATVBAHA.115.307034","volume":"36","author":"J Zilberman-Rudenko","year":"2016","unstructured":"Zilberman-Rudenko, J., Itakura, A., Wiesenekker, C. P., Vetter, R., Maas, C., Gailani, D., Tucker, E. I., Gruber, A., Gerdes, C., & McCarty, O. J. (2016). Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow. Arteriosclerosis thrombosis and vascular biology, 36(3), 510\u2013517.","journal-title":"Arteriosclerosis thrombosis and vascular biology"},{"issue":"22","key":"540_CR34","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","volume":"116","author":"H Zhang","year":"2010","unstructured":"Zhang, H., Lowenberg, E. C., Crosby, J. R., MacLeod, A. R., Zhao, C., Gao, D., Black, C., Revenko, A. S., Meijers, J. C., Stroes, E. S., et al. (2010). Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood, 116(22), 4684\u20134692.","journal-title":"Blood"},{"issue":"7","key":"540_CR35","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","volume":"33","author":"JR Crosby","year":"2013","unstructured":"Crosby, J. R., Marzec, U., Revenko, A. S., Zhao, C., Gao, D., Matafonov, A., Gailani, D., MacLeod, A. R., Tucker, E. I., Gruber, A., et al. (2013). Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arteriosclerosis thrombosis and vascular biology, 33(7), 1670\u20131678.","journal-title":"Arteriosclerosis thrombosis and vascular biology"},{"issue":"3","key":"540_CR36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2012-03-419523","volume":"120","author":"W Wu","year":"2012","unstructured":"Wu, W., Li, H., Navaneetham, D., Reichenbach, Z. W., Tuma, R. F., & Walsh, P. N. (2012). The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis. Blood, 120(3), 671\u2013677.","journal-title":"Blood"},{"key":"540_CR37","doi-asserted-by":"crossref","unstructured":"Chalothorn, D., Kithcart, A. P., Marin, E., Somersan-Karakaya, S., Lai, K., Cauwberghs, F., Ackroyd, J. P. R., Mohammadi, K., Shrestha, A., Ehrlich, G. K. (2026). Anticoagulation with mechanistically distinct FXI\/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat). Blood.","DOI":"10.1182\/blood.2025032276"},{"key":"540_CR38","doi-asserted-by":"crossref","first-page":"123157","DOI":"10.1016\/j.jns.2024.123157","volume":"464","author":"CH Nolte","year":"2024","unstructured":"Nolte, C. H. (2024). Factor XI inhibitors - Rising stars in anti-thrombotic therapy? Journal of the neurological sciences, 464, 123157.","journal-title":"Journal of the neurological sciences"},{"issue":"5","key":"540_CR39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","volume":"84","author":"V Perera","year":"2018","unstructured":"Perera, V., Luettgen, J. M., Wang, Z., Frost, C. E., Yones, C., Russo, C., Lee, J., Zhao, Y., LaCreta, F. P., Ma, X., et al. (2018). First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. British journal of clinical pharmacology, 84(5), 876\u2013887.","journal-title":"British journal of clinical pharmacology"},{"issue":"10","key":"540_CR40","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas, D., Kanefendt, F., Schwers, S., Unger, S., Yassen, A., & Boxnick, S. (2021). First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. Journal of thrombosis and haemostasis: JTH, 19(10), 2407\u20132416.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"6","key":"540_CR41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-022-01110-9","volume":"61","author":"V Perera","year":"2022","unstructured":"Perera, V., Abelian, G., Li, D., Wang, Z., Zhang, L., Lubin, S., Chen, W., Bello, A., & Murthy, B. (2022). Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical Pharmacokinetics, 61(6), 857\u2013867.","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"540_CR42","doi-asserted-by":"crossref","first-page":"22239","DOI":"10.1038\/s41598-022-25936-2","volume":"12","author":"V Perera","year":"2022","unstructured":"Perera, V., Wang, Z., Lubin, S., Christopher, L. J., Chen, W., Xu, S., Seiffert, D., DeSouza, M., & Murthy, B. (2022). Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports, 12(1), 22239.","journal-title":"Scientific reports"},{"issue":"4","key":"540_CR43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/bcp.15981","volume":"90","author":"F Kanefendt","year":"2024","unstructured":"Kanefendt, F., Brase, C., Jungmann, N., Fricke, R., Engelen, A., & Schmitz, S. (2024). Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies. British journal of clinical pharmacology, 90(4), 1036\u20131049.","journal-title":"British journal of clinical pharmacology"},{"issue":"13","key":"540_CR44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","volume":"133","author":"AW Koch","year":"2019","unstructured":"Koch, A. W., Schiering, N., Melkko, S., Ewert, S., Salter, J., Zhang, Y., McCormack, P., Yu, J., Huang, X., Chiu, Y. H., et al. (2019). MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood, 133(13), 1507\u20131516.","journal-title":"Blood"},{"issue":"2","key":"540_CR45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","volume":"20","author":"BA Yi","year":"2022","unstructured":"Yi, B. A., Freedholm, D., Widener, N., Wang, X., Simard, E., Cullen, C., Al-Saady, N. M., Lepor, N. E., Coulter, S., Lovern, M., et al. (2022). Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of thrombosis and haemostasis: JTH, 20(2), 307\u2013315.","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"3","key":"540_CR46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston, S. C., Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., et al. (2020). Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal Of Medicine, 383(3), 207\u2013217.","journal-title":"New England Journal Of Medicine"},{"key":"540_CR47","doi-asserted-by":"crossref","unstructured":"Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., Kim, A. S., Lindblad, A. S., Palesch, Y. Y. (2018). Clinical Research Collaboration NETTN : Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 379(3):215\u2013225.","DOI":"10.1056\/NEJMoa1800410"},{"issue":"7","key":"540_CR48","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021). 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke, 52(7), e364\u2013e467.","journal-title":"Stroke"},{"issue":"14","key":"540_CR49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal Of Medicine, 377(14), 1319\u20131330.","journal-title":"New England Journal Of Medicine"},{"issue":"9","key":"540_CR50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","volume":"139","author":"M Sharma","year":"2019","unstructured":"Sharma, M., Hart, R. G., Connolly, S. J., Bosch, J., Shestakovska, O., Ng, K. K. H., Catanese, L., Keltai, K., Aboyans, V., Alings, M., et al. (2019). Stroke Outcomes in the COMPASS Trial. Circulation, 139(9), 1134\u20131145.","journal-title":"Circulation"},{"issue":"10357","key":"540_CR51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh, A., Mundl, H., Smith, E. E., Masjuan, J., Milanov, I., Hirano, T., Agafina, A., Campbell, B., Caso, V., Mas, J. L., et al. (2022). Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet, 400(10357), 997\u20131007.","journal-title":"Lancet"},{"issue":"1","key":"540_CR52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma, M., Molina, C. A., Toyoda, K., Bereczki, D., Bangdiwala, S. I., Kasner, S. E., Lutsep, H. L., Tsivgoulis, G., Ntaios, G., Czlonkowska, A., et al. (2024). Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet Neurology, 23(1), 46\u201359.","journal-title":"The Lancet Neurology"},{"issue":"4","key":"540_CR53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/23969873251344485","volume":"10","author":"RG Hart","year":"2025","unstructured":"Hart, R. G., Smith, E. E., Wang, A., Mundl, H., Colorado, P., Joundi, R. A., Katsanos, A. H., Sharma, M., & Shoamanesh, A. (2025). Location, size, and risk factors of incident covert brain infarcts in patients with acute non-cardioembolic ischemic stroke: PACIFIC-STROKE trial. Eur Stroke J, 10(4), 1413\u20131420.","journal-title":"Eur Stroke J"},{"key":"540_CR54","doi-asserted-by":"crossref","unstructured":"Sharma, M., Dong, Q., Hirano, T., Kasner, S. E., Saver, J., Masjuan, J., Demchuk, A. M., Cordonnier, C., Bereczki, D., Tsivgoulis, G. (2026). Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. Eur Stroke J 11(1).","DOI":"10.1093\/esj\/aakag023.1857"},{"issue":"1","key":"540_CR55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024). 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1\u2013e156.","journal-title":"Circulation"},{"issue":"1","key":"540_CR56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s42466-025-00438-4","volume":"7","author":"D Pommeranz","year":"2025","unstructured":"Pommeranz, D., Lehr, N., Escola, J. K., Brune, B., Dammann, P., Li, Y., Deuschl, C., Forsting, M., Kill, C., Kleinschnitz, C., et al. (2025). Recent intake of direct oral anticoagulants and acute ischemic stroke: real world data from a comprehensive stroke center. Neurol Res Pract, 7(1), 82.","journal-title":"Neurol Res Pract"},{"issue":"10333","key":"540_CR57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini, J. P., Caso, V., Connolly, S. J., Fox, K. A. A., Oldgren, J., Jones, W. S., Gorog, D. A., Durdil, V., Viethen, T., Neumann, C., et al. (2022). Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet, 399(10333), 1383\u20131390.","journal-title":"Lancet"},{"issue":"4","key":"540_CR58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff, C. T., Patel, S. M., Giugliano, R. P., Morrow, D. A., Hug, B., Kuder, J. F., Goodrich, E. L., Chen, S. A., Goodman, S. G., Joung, B., et al. (2025). Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. New England Journal Of Medicine, 392(4), 361\u2013371.","journal-title":"New England Journal Of Medicine"},{"key":"540_CR59","doi-asserted-by":"crossref","unstructured":"Piccini, J. P., Patel, M. R., Steffel, J., Ferdinand, K., Van Gelder, I. C., Russo, A. M., Ma, C. S., Goodman, S. G., Oldgren, J., Hammett, C. (2025). Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med 392(1):23\u201332.","DOI":"10.1056\/NEJMoa2407105"},{"key":"540_CR65","doi-asserted-by":"crossref","unstructured":"Vassart J, Ndzatou DB, Didembourg M, Morimont L, Brisbois C, Jamart L, Demeure F, Lebreton A, Mullier F, Favresse J et al (2025). Impact of asundexian on a panel of coagulation assays. Res Pract Thromb Haemost, 9(5):102950.","DOI":"10.1016\/j.rpth.2025.102950"},{"key":"540_CR60","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJM196810032791407","volume":"279 No","author":"OD Ratnoff","year":"1968","unstructured":"Ratnoff, O. D., Busse, R. J. Jr., & Sheon, R. P. (1968). The Demise of John Hageman. New England Journal Of Medicine, 279 No, 14:760\u2013761.","journal-title":"New England Journal Of Medicine"},{"issue":"5","key":"540_CR61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","volume":"19","author":"N Mackman","year":"2020","unstructured":"Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020). Therapeutic strategies for thrombosis: new targets and approaches. Nature reviews Drug discovery, 19(5), 333\u2013352.","journal-title":"Nature reviews Drug discovery"},{"issue":"5","key":"540_CR62","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/STROKEAHA.122.038733","volume":"53","author":"SF De Meyer","year":"2022","unstructured":"De Meyer, S. F., Langhauser, F., Haupeltshofer, S., Kleinschnitz, C., & Casas, A. I. (2022). Thromboinflammation in Brain Ischemia: Recent Updates and Future Perspectives. Stroke, 53(5), 1487\u20131499.","journal-title":"Stroke"},{"issue":"1","key":"540_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s42466-024-00355-y","volume":"6","author":"G Stoll","year":"2024","unstructured":"Stoll, G., Nieswandt, B., & Schuhmann, M. K. (2024). Ischemia\/reperfusion injury in acute human and experimental stroke: focus on thrombo-inflammatory mechanisms and treatments. Neurol Res Pract, 6(1), 57.","journal-title":"Neurol Res Pract"},{"issue":"1","key":"540_CR64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ana.25643","volume":"87","author":"A Schmidt-Pogoda","year":"2020","unstructured":"Schmidt-Pogoda, A., Bonberg, N., Koecke, M. H. M., Strecker, J. K., Wellmann, J., Bruckmann, N. M., Beuker, C., Schabitz, W. R., Meuth, S. G., Wiendl, H., et al. (2020). Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Annals of neurology, 87(1), 40\u201351.","journal-title":"Annals of neurology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00540-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:16:13Z","timestamp":1792178173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00540-1","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"17 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declaraations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Clinical trial number<\/b>","group":{"name":"EthicsHeading","label":"Declaraations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declaraations"}}],"article-number":"84"}}